Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
Public ClinicalTrials.gov record NCT01739595. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of ZA-302 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T\<300 ng/dL) and normal sperm concentration, compared to changes with placebo. Subjects must not have previously been treated with testosterone products within the last 6 months.
Study identification
- NCT ID
- NCT01739595
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 181 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2012
- Primary completion
- Aug 31, 2013
- Completion
- Aug 31, 2013
- Last update posted
- May 26, 2015
2012 – 2013
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Coastal Clinical Research | Mobile | Alabama | 36608 | — |
| Baptist Health Center for Clinical Research | Little Rock | Arkansas | 72205 | — |
| Rancho Cucamonga Clinical Trials | Rancho Cucamonga | California | 91730 | — |
| Meridien Research | Bradenton | Florida | 34208 | — |
| All Medical Research | Cooper City | Florida | 33024 | — |
| Clinical Research of South Florida | Coral Gables | Florida | 33134 | — |
| Phase One Solutions | Miami Gardens | Florida | 33169 | — |
| Central Kentucky Research Associates | Lexington | Kentucky | 40509 | — |
| Rochester Clinical Research | Rochester | New York | 14609 | — |
| Coastal Carolina Research Center | Mt. Pleasant | South Carolina | 29464 | — |
| New Orleans Center for Clinical Research | Knoxville | Texas | 37920 | — |
| Lone Peak Family Medicine | Draper | Utah | 84020 | — |
| Granger Medical Clinic | Riverton | Utah | 84065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01739595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2015 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01739595 live on ClinicalTrials.gov.